And there are more...

Anytime you talk about buyout buzz in biotech, there are always plenty of candidates for the Top 10 list. Perhaps too many. After a certain point, it can be hard to discern exactly why some of these companies are on anyone's list. Seattle Genetics' ($SGEN) name has come up from time to time, though the company has done absolutely nothing to encourage it. But once Adcetris was approved, the antibody-drug conjugate pioneer automatically became a target in some analysts' calculations.

Earlier, Chris Raymond, an analyst at Robert W. Baird, pulled Alexion ($ALXN) out of the hat, along with Human Genome Sciences (correct), BioMarin (above) and Dendreon ($DNDN), which seems to have more trouble trying to market Provenge than it can handle. Alexion has made Soliris, the world's priciest rare disease drug, into a blockbuster product. And if you've been paying attention, successful single-product companies--especially in rare diseases--are mighty attractive.

Regeneron ($REGN) has had to do the honors this year in declining comment that its Big Pharma partner Sanofi ($SNY) is thinking of moving in to snap it up.

There are plenty of good reasons for a tie-up, but Regeneron seems happy with the way things are. Perhaps if their PCSK9 partnership looks as good as Sanofi thinks, though, a deal could ripen.

In the summer Piper Jaffray was telling clients that Affymax ($AFFY), Theravance ($THRX), and Rigel Pharmaceuticals ($RIGL) were also candidates. As I noted at the time, with this much smoke, it seems likely that we'll see some more fire on the M&A front. But clear vision will also be in short supply.

For more:
Analysts: Medical device M&A will heat up in 2013
Buzz: Big investors likely to back next wave of biotech buyouts
Who's next on Big Pharma's biotech shopping list?
Slate of looming FDA decisions keeps M&A watchers on high alert
Which biotech will be the next to get swept away in the M&A wave?

And there are more...
Read more on

Suggested Articles

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts.

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.

The creation of the latest outpost of the BRIDGE model sees Evotec team up with Integra Holdings and Yissum to help researchers at Hebrew University.